vs
Alpha Cognition Inc.（ACOG）与AGENUS INC（AGEN）财务数据对比。点击上方公司名可切换其他公司
AGENUS INC的季度营收约是Alpha Cognition Inc.的12.2倍（$34.2M vs $2.8M）。AGENUS INC净利率更高（-31.0% vs -245.5%，领先214.4%）
Agenus Inc.是一家总部位于美国马萨诸塞州列克星敦的生物技术公司，核心业务聚焦免疫治疗领域，尤其专注于利用人体免疫系统控制或治愈癌症的肿瘤免疫治疗。公司目前正在研发检查点调节剂、个性化抗癌疫苗，以及可适配多种疫苗的免疫佐剂，其中检查点调节剂作为当前进展迅速的方向，早期产品已为患者带来突破性临床获益。
ACOG vs AGEN — 直观对比
营收规模更大
AGEN
是对方的12.2倍
$2.8M
净利率更高
AGEN
高出214.4%
-245.5%
损益表 — Q4 2025 vs Q4 2025
| 指标 | | |
|---|---|---|
| 营收 | $2.8M | $34.2M |
| 净利润 | $-6.9M | $-10.6M |
| 毛利率 | — | — |
| 营业利润率 | -283.7% | 42.1% |
| 净利率 | -245.5% | -31.0% |
| 营收同比 | — | 27.5% |
| 净利润同比 | — | 77.3% |
| 每股收益（稀释后） | $-0.10 | $0.09 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收ACOGAGEN
| Q4 25 | $2.8M | $34.2M | ||
| Q3 25 | $2.8M | $30.2M | ||
| Q2 25 | $1.7M | $25.7M | ||
| Q1 25 | $2.9M | $24.1M | ||
| Q4 24 | — | $26.8M | ||
| Q3 24 | — | $25.1M | ||
| Q2 24 | — | $23.5M | ||
| Q1 24 | — | $28.0M |
净利润ACOGAGEN
| Q4 25 | $-6.9M | $-10.6M | ||
| Q3 25 | $-1.3M | $63.9M | ||
| Q2 25 | $-10.5M | $-30.0M | ||
| Q1 25 | $-2.0M | $-26.4M | ||
| Q4 24 | — | $-46.8M | ||
| Q3 24 | — | $-67.2M | ||
| Q2 24 | — | $-54.8M | ||
| Q1 24 | — | $-63.5M |
毛利率ACOGAGEN
| Q4 25 | — | — | ||
| Q3 25 | — | 97.9% | ||
| Q2 25 | 96.7% | 99.1% | ||
| Q1 25 | 99.6% | 99.4% | ||
| Q4 24 | — | 99.6% | ||
| Q3 24 | — | 99.4% | ||
| Q2 24 | — | 99.5% | ||
| Q1 24 | — | 99.6% |
营业利润率ACOGAGEN
| Q4 25 | -283.7% | 42.1% | ||
| Q3 25 | -187.0% | -15.0% | ||
| Q2 25 | -346.1% | -65.0% | ||
| Q1 25 | -125.9% | -55.3% | ||
| Q4 24 | — | -96.5% | ||
| Q3 24 | — | -125.5% | ||
| Q2 24 | — | -128.4% | ||
| Q1 24 | — | -117.4% |
净利率ACOGAGEN
| Q4 25 | -245.5% | -31.0% | ||
| Q3 25 | -46.4% | 211.4% | ||
| Q2 25 | -632.7% | -116.8% | ||
| Q1 25 | -68.5% | -109.6% | ||
| Q4 24 | — | -174.4% | ||
| Q3 24 | — | -267.7% | ||
| Q2 24 | — | -233.1% | ||
| Q1 24 | — | -226.6% |
每股收益（稀释后）ACOGAGEN
| Q4 25 | $-0.10 | $0.09 | ||
| Q3 25 | $-0.30 | $1.94 | ||
| Q2 25 | $-0.65 | $-1.00 | ||
| Q1 25 | $-0.13 | $-1.03 | ||
| Q4 24 | — | $-1.95 | ||
| Q3 24 | — | $-3.08 | ||
| Q2 24 | — | $-2.52 | ||
| Q1 24 | — | $-3.04 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $66.0M | $3.0M |
| 总债务越低越好 | — | $44.7M |
| 股东权益账面价值 | $62.5M | $-271.1M |
| 总资产 | $79.7M | $226.8M |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资ACOGAGEN
| Q4 25 | $66.0M | $3.0M | ||
| Q3 25 | $35.4M | $3.5M | ||
| Q2 25 | $39.4M | $9.5M | ||
| Q1 25 | $45.5M | $18.5M | ||
| Q4 24 | — | $40.4M | ||
| Q3 24 | — | $44.8M | ||
| Q2 24 | — | $93.7M | ||
| Q1 24 | — | $52.9M |
总债务ACOGAGEN
| Q4 25 | — | $44.7M | ||
| Q3 25 | — | $34.2M | ||
| Q2 25 | — | $33.9M | ||
| Q1 25 | — | $33.6M | ||
| Q4 24 | — | $33.2M | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
股东权益ACOGAGEN
| Q4 25 | $62.5M | $-271.1M | ||
| Q3 25 | $33.9M | $-274.1M | ||
| Q2 25 | $31.9M | $-354.6M | ||
| Q1 25 | $40.8M | $-341.8M | ||
| Q4 24 | — | $-326.4M | ||
| Q3 24 | — | $-292.3M | ||
| Q2 24 | — | $-241.3M | ||
| Q1 24 | — | $-201.4M |
总资产ACOGAGEN
| Q4 25 | $79.7M | $226.8M | ||
| Q3 25 | $46.3M | $233.9M | ||
| Q2 25 | $45.1M | $185.2M | ||
| Q1 25 | $48.6M | $200.2M | ||
| Q4 24 | — | $226.3M | ||
| Q3 24 | — | $238.5M | ||
| Q2 24 | — | $292.4M | ||
| Q1 24 | — | $256.6M |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $-6.9M | $-16.6M |
| 自由现金流经营现金流 - 资本支出 | $-7.1M | — |
| 自由现金流率自由现金流/营收 | -252.6% | — |
| 资本支出强度资本支出/营收 | 5.3% | 0.0% |
| 现金转化率经营现金流/净利润 | — | — |
| 过去12个月自由现金流最近4个季度 | $-20.7M | — |
8季度趋势，按日历期对齐
经营现金流ACOGAGEN
| Q4 25 | $-6.9M | $-16.6M | ||
| Q3 25 | $-5.3M | $-14.7M | ||
| Q2 25 | $-6.1M | $-20.2M | ||
| Q1 25 | $-2.0M | $-25.6M | ||
| Q4 24 | — | $-28.7M | ||
| Q3 24 | — | $-53.3M | ||
| Q2 24 | — | $-38.2M | ||
| Q1 24 | — | $-38.2M |
自由现金流ACOGAGEN
| Q4 25 | $-7.1M | — | ||
| Q3 25 | $-5.4M | — | ||
| Q2 25 | $-6.1M | $-20.2M | ||
| Q1 25 | $-2.1M | $-25.6M | ||
| Q4 24 | — | $-28.7M | ||
| Q3 24 | — | $-53.3M | ||
| Q2 24 | — | $-38.6M | ||
| Q1 24 | — | $-38.2M |
自由现金流率ACOGAGEN
| Q4 25 | -252.6% | — | ||
| Q3 25 | -188.8% | — | ||
| Q2 25 | -370.9% | -78.7% | ||
| Q1 25 | -72.0% | -106.5% | ||
| Q4 24 | — | -107.0% | ||
| Q3 24 | — | -212.2% | ||
| Q2 24 | — | -164.4% | ||
| Q1 24 | — | -136.5% |
资本支出强度ACOGAGEN
| Q4 25 | 5.3% | 0.0% | ||
| Q3 25 | 2.6% | 0.0% | ||
| Q2 25 | 0.5% | 0.0% | ||
| Q1 25 | 2.2% | 0.0% | ||
| Q4 24 | — | 0.3% | ||
| Q3 24 | — | 0.0% | ||
| Q2 24 | — | 2.0% | ||
| Q1 24 | — | 0.1% |
现金转化率ACOGAGEN
| Q4 25 | — | — | ||
| Q3 25 | — | -0.23× | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
